Abstract
We investigated the clinical implications of preferentially expressed antigen in melanoma (PRAME) expression in bone marrow cells of 116 patients with myelodysplastic syndromes (MDS). Quantitative RT-PCR was carried out to examine the PRAME expression level. High PRAME expression was observed in MDS patients classified into higher revised International Prognostic Scoring System (IPSS-R) risk categories (Very high and High) with a high bone marrow blast percentage (5% or higher). Kaplan-Meier analysis demonstrated that high PRAME expression is significantly associated with a poorer overall survival (OS) in MDS patients with a low bone marrow blast percentage (less than 5%) (log-rank test p = .0014) and those classified into lower IPSS-R risk categories (Very Low, Low, and Intermediate) (log-rank test, p = .0035). In contrast, there was no significant association between PRAME expression and OS in MDS patients with a high bone marrow blast percentage or those classified into higher IPSS-R risk categories. In addition, high PRAME expression was associated with early disease progression in MDS patients with a low bone marrow blast percentage. This study suggested PRAME expression to be a prognostic factor in MDS.
Keywords:
PRAME; clinical significance; myelodysplastic syndromes.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antigens, Neoplasm / genetics
-
Bone Marrow*
-
Disease Progression
-
Humans
-
Kaplan-Meier Estimate
-
Myelodysplastic Syndromes* / diagnosis
-
Myelodysplastic Syndromes* / genetics
-
Prognosis
Substances
-
Antigens, Neoplasm
-
PRAME protein, human